Pharma Stocks

Showing 859 articles
Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.

Business

Bausch Health's Deep Discount: Market Overshoot or Justified Skepticism?

With shares languishing near $5.74, Bausch Health Companies (BHC) presents a stark valuation puzzle. While a standard DCF model suggests a staggering 91% undervaluation, the market's persistent sell-off reflects deep-seated concerns over the company's restructuring path and debt burden. We examine the numbers behind the divergence.

Business

Heidelberg Materials Gains Momentum as Investors Bet on Green Cement Boom

Heidelberg Materials (XTRA:HEI) is attracting renewed investor interest, fueled by accelerating global demand for sustainable construction materials. The company's strategic positioning in low-carbon cement and aggregates coincides with strong shareholder returns, raising questions about its current valuation in a rapidly evolving market.